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Anti-invasive therapeutics provide a means to improve the prognosis of invasive 
cancer patients. Recently, one such compound have been identified for its ability to halt 
the invasion of glioblastoma. This compound, known as Imipramine Blue (IB), 
successfully reduced cancer cell invasion in vitro and in vivo, and displayed the potential 
to reduce invasion in other invasive cancer models as well.
1
 Therefore, it was determined 
that the effects of IB should be studied in depth on other invasive cancer models, and a 
metastatic prostate cancer cell line, MatLyLu, was chosen for the study. Prostate cancer, 
like glioblastoma, has a poor prognosis due to its extremely invasive nature. Specific 
aims for this project were identified, and a literature review was conducted to evaluate 
other anti-invasive compounds that are currently under investigation.  
The primary goal of this project was to determine the ability of IB to halt invasion 
of the MatLyLu cell line at non-cytotoxic levels. To do this, an in vitro invasion assay 
was performed on MatLyLu. Preliminary results showed that MatLyLu experiences a 
dose dependent decrease in invasion, but for this experiment, IB was determined to be 
cytotoxic. Thus, the invasion assay procedure was then optimized to eliminate 
cytotoxicity, and any possible human error. The invasive glioblastoma cell line, which 
has been shown to respond to IB treatment, was also incorporated as a positive control. 
Another test was performed, and results showed that IB was no longer cytotoxic. 
However, a dose dependent decrease in invasion was no longer seen for either cell line. 
Therefore, the invasion assay procedure was optimized further, and the experiments were 
performed again. Results from these experiments showed that the RT2 cells do 
experience a dose dependent decrease in invasion at non-cytotoxic levels. However, the 
 x 
MatLyLu cell line still did not show a dose dependent decrease in invasion. There is still 
additional experimental optimization that can be performed, so results thus far have not 
provided enough evidence to determine the anti-invasive effects of IB on the MatLyLu 
cell line. 
The second aim of this project is to develop an in vivo tumor model for MatLyLu. 
This cell line is known to metastasize, “mat,” in the lymph nodes, “ly,” and the lungs, 
“lu.” A metastatic model was developed in Copenhagen rats, and the model develops 
metastases in the lungs 18 days after tumor cell implantation. For final in vivo 
experiments this model must be tested with Luciferase expressing MatLyLu cells in order 
to evaluate metastasis non-invasively. Therefore, to complete this project, optimization of 
the in vitro and in vivo models must be finalized. However, once the last few experiments 
are completed, this project will be ready to move forward with in vivo testing of the anti-







Invasive cancers are the most deadly class of cancers because they are not effectively 
eliminated by current treatment procedures. This is because resection, radiation, and 
chemotherapy do not typically affect the ability of surviving cancer cells to invade and 
metastasize elsewhere. Current researchers have proposed that adding an anti-invasive 
component to cancer treatment will increase the effectiveness of the treatment.
1-5,7,13
 
Recently, there has been a shift toward developing novel drugs that target specific cell 
signaling pathways that induce invasion. These drugs would allow for more personalized 
cancer treatment because treatment would be adjusted for each patient. In these cases, the 
goal would be to increase the effectiveness of treatment while decreasing the adverse side 
effects.   
Current research is geared towards evaluating new compounds and compound 
derivatives that specifically inhibit the mechanics of cell invasion and metastasis. Using 
this approach, Munson et al. discovered the novel compound, Imipramine Blue (IB), and 
evaluated its anti invasive properties using an invasive glioma model.
1
 It was determined 
that IB showed dose dependent invasion inhibition in vitro. In vivo studies were then 
performed, and it was determined that IB decreased the invasive properties of the glioma 
cells resulting in more compact tumors which could be treated more effectively with 
cytotoxic chemotherapeutics. Although the mechanism of IB is still unknown, it is 
believed to inhibit cell invasion. IB belongs to a class of compounds known as 
triphenylmethanes, and is expected to be a universally good candidate for invasion 
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reduction. Therefore, Munson et al. also performed in vitro invasion assays on a 
metastatic prostate cancer model, DU145, and two metastatic breast cancer models, ZR-
75 and MDA-MB435 to test this theory. The results from these studies showed a 50% 
decrease in invasion. Therefore, it was determined that the effects of IB should be studied 
on other invasive cancer models to determine its full effect on cancer invasion and 
metastasis.  
The current project evaluates IB for its ability to halt tumor metastasis on a metastatic 
prostate cancer cell line. Initial studies investigated the use of IB to prevent metastasis of 
the cell line, Dunning R 3327 MatLyLu. In vitro invasion assays and cytotoxicity assays 
were performed to determine the ability of IB to prevent the invasion potential of this cell 
line.  These tests were also performed with the glioblastoma line, RT2, tested by Munson 
et al. Results of the RT2 tests were compared to the MatLyLu tests to determine whether 
or not IB is capable of inhibiting cell invasion below cytotoxic levels in this cell line.   
1.2 Specific Aims  
 There are two primary aims for this project, with one secondary aim. The primary 
aims of this project are to optimize the dose of IB on the metastatic prostate cell line, 
MatLyLu, used for invasion prevention in vitro, and determine if this dose is below 
cytotoxic levels. The goal is to determine the smallest dose of IB that causes at least a 
50% reduction in invasion, so that this dose can later be used in in vivo studies. The 
secondary aim of this project is to develop an in vivo tumor model with MatLyLu for 





1.3 Literature Review 
1.3.1 Introduction 
In the past five years, there has been a significant increase in compounds that can 
potentially halt tumor invasion. The traditional strategy of evaluating such compounds is 
to determine their inhibition of matrix metalloproteinases (MMPs), and thereby their 
limiting the invasiveness of the cancer cells. Some new anti-invasive agents, such as 
epigallocatechin 3-gallate aim to induce apoptosis, or programmed cell death.
2
 However, 
these compounds are non-specific and much of the research on those compounds is 
focused on cytotoxicity. Research is now geared towards evaluating compounds that 
inhibit specific cell receptors or signaling pathways in order to kill cancer cells. 
Triphenylmethanes are a class of compounds that have recently been discovered to inhibit 
tumor angiogenisis.
7
 The purpose of this section is to review major advances in anti-
invasive compound research, including the evaluation of MMP inhibitors Batimastat and 
Marimastat, epigallocatechin 3-gallat, and the novel triphenylmethane compounds. 
1.3.2 Inhibiting matrix metalloproteinases  
MMPs are enzymes that are responsible for the turnover of the extracellular matrix, 
and they are regulated by gene expression and secretion of proenzymes. In pancreatic 
cancer, tumors secrete excessive amounts of MMP-2 and MMP-9 and decreased amounts 
of their inhibitors TIMP-1 and TIMP-2, which cause increased turnover of the 
extracellular matrix. Elevated levels of MMP-2 are associated with cell invasion and 
subsequent metastasis, and are found in most forms of invasive cancer.
4
 Therefore, 
inhibiting MMPs would limit the invasive ability of cancer cells.
3,4
 Batimastat and 
marimastat, both MMP-2 inhibitors, were considered to be “forerunners” for the 
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treatment of invasive tumors.
4
 Pre-clinical trials using a glioma model were performed on 
rodents using marimastat and batimastat. Although the marimastat trials yielded no 
results due to the speedy metabolism of the compound by the rodents, batimastat yielded 
promising anti-invasive results. Because of the similarity between batimastat and 
marimastat, the results of batimastat indicated that marimastat should be successful in 
upcoming clinical trials.
3
 However, by Phase II of clinical trials marimastat was 
unsuccessful in enhancing positive clinical outcomes in glioblastoma cancer.
5
 Following  
these trials, MMP inhibitors have still been heavily pursued, but more and more evidence 
suggests that the assumptions about what role MMP plays in invasion must be re-
evaluated.
6 
1.3.3 Apoptosis Stimulation and Induction 
Non-traditional anti-invasion research evaluates compounds that competitively inhibit 
the genetic receptors that start apoptosis, and compounds that can stimulate apoptosis. 
One such compound, evaluated for its anti-invasive properties showed promising results. 
This compound, epigallocatechin 3-gallate (EGCG), is the major component in green tea 
and is currently being investigated as a cancer preventative therapeutic. EGCG binds to 
the GRP78 receptor, which then sensitizes the cancer cell to other chemotherapeutic 
agents that stimulate apoptosis. It has been shown that EGCG has sensitized a variety of 
different cancer models to many agents that stimulate apoptosis, such as 5-
fluorouracil, taxol, vinblastine, gemcitabine, or tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) in vitro, and doxorubicin, paclitaxel, 
or interferon in mouse tumor models in vivo.
2
 EGCG has also been shown to increase the 
survival of mice with glioblastoma when used in conjunction with temozolomide. 
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However, low concentrations of EGCG in the absence of an apoptosis stimulant showed 
an increase in cancer cell proliferation.
2
  
1.3.4 Novel Compounds for Invasion Inhibition 
Inhibition of tumor angiogenesis as an approach for cancer treatment was first 
evaluated by Judah Folkman.
11
 Angiogenisis is the proliferation of new blood vessels, 
which is triggered by nitric oxide and reactive oxygen species. These free radicals are 
found in elevated levels inside of tumors, and regulate pathways for initiation of tumor 
invasion. Triphenylmethanes are a group of compounds that act to inhibit NADPH 
Oxidase (Nox), which is the enzyme that regulates the invasion initiation pathways.
13
  
Triphenylmethanes were originally identified in 1992 by Cooney et al. as “a novel 
chemopreventive agent”.
13
 The invasion initiation pathways include Src kinase, 
p38/MAPK, and activation of NFkB, with subsequent secretion of MMPs, which is very 
important for invasion inhibition, as indicated by previous research.
7
 This makes 
triphenylmethanes and their derivatives good candidates for anti-invasion research.  One 





The discovery of IB reveals a new possibility for anti-invasion research. Although the 
mechanism of IB’s invasion inhibition is yet to be fully elucidated, research performed by 
Munson et al. suggests that it may affect a signaling pathway that is present in all 
invasive cancers. Moving forward with this discovery, the anti-invasive properties of IB 
should be evaluated on other metastatic cell lines. It should also be tested in conjunction 
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with radiation therapy to determine if it can negate the increased invasiveness of cancer 
cells caused by radiation exposure.  
 7 
CHAPTER 2 
PRELIMINARY IN VITRO INVASION ASSAYS  
2.1 Introduction 
 Preliminary studies evaluated the use of IB in preventing the metastasis of 
prostate cancer model, Dunning R 3327 MatLyLu, below cytotoxic levels. This tumor 
model has an extremely high metastatic rate, greater than 75% in all inoculated animals, 
as reported by Isaacs et al.
15
 The glioblastoma model, RT2, used by Munson et al. was 
also tested and used as a positive control for the experiments. Both MatLyLu and RT2 
cells were maintained in culture. Invasion assays were performed with varying doses of 
IB over a time period of 24 hours. 
2.2 Methods  
2.2.1 Cell Culture 
RT2 cells were sustained in T-75 flasks with Dulbecco’s Modified Eagle’s Medium 
supplemented with 1% L-glutamine, 1%  Penicillin/Streptomycin, 1% Non-Essential 
Amino Acids, and 10% Fetal Bovine Serum (FBS). MatLyLu cells were sustained in T-
75 flasks with Roswell Park Memorial Institute 1640 (RPMI) medium supplemented with 
1% Penicillin/Streptomycin, 1% Dexamethisone, and 10% Fetal Bovine Serum (FBS). 
Cell lines were split once every 7 days, and media was changed once every 3-4 days. 
2.2.2 In Vitro Invasion Assays 
In vitro invasion assays were performed on MatLyLu cells to determine the optimal 
dose of IB for in vivo testing. RT2 cells were used as a positive control. Cells were 
treated with varied doses of IB, and 24 hours later fluorescent images were taken using 
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DAPI nuclear stain. To begin testing, cell culture inserts with 0.8 μm pores were placed 
in 24-well plates (Micell). The membranes of inserts were coated with 80 μL of 1X 
basement membrane extract (BME) (Cultrex) in 72% sterile, deionized water, and 8% 
coating buffer. Inserts were incubated for at least two hours to allow the BME to gel, and 
then excess is removed by aspiration. Cells were suspended in serum-free media at a 
concentration of 25e5 cells/mL. Serum-containing media is loaded on the outside of the 
inserts, which were incubated for 30 minutes to allow cell adhesion. Cells were then 
treated with varying doses of IB. Doses tested were 10 μM, 1 μM, 0.1 μM and 0 μM; 
each dose had a sample size of n=3. The invasion assay procedure is depicted in Fig. 2.1. 
Inserts were then incubated overnight, allowing invading cells to migrate through the 
basement membrane, where they attach to the bottom of the well insert. Non-invading 
cells remain on the top of the inserts.  
After 24 hours cells are fixed with 4% paraformaldehyde and stained with DAPI 
nuclear stain for 5 minutes. After staining, the top of each insert is wiped with a cotton 
swab to remove any cells on top of the insert. Five images are then taken from each well, 
and the cells in each image were counted. The cell counts from the five images are then 
averaged for each well, and standard deviation was calculated. 
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Figure 2.1: In vitro invasion assay. Cells were suspended inside a well-insert and 
treated with IB. Overnight, invading cells migrate through the basement membrane of the 
insert and adhere to the bottom. Cells that do not invade remain on top. Cells on the 
bottom were stained with DAPI and fluorescently imaged.  
2.3 Results 
Invasion assays were performed on MatLyLu and RT2 cells. The MatLyLu invasion 
assay appeared to show a dose-dependent decrease in invasion (Fig. 2.2). Cytotoxicity 
was also tested, and it was determined that all doses of IB tested were cytotoxic. Thus, 
preliminary invasion assays have yielded no conclusive results. 
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Figure 2.2: Imipramine Blue was tested on MatLyLu in vitro. An in vitro invasion 
assay was performed on MatLyLu to test the ability of IB to prevent invasion. This study 
yielded no conclusive results because all doses of IB were determined to be cytotoxic. 
2.4 Discussion 
Although there was a dose dependent decrease in invasion, all doses of IB tested 
were cytotoxic. Previously, IB showed a dose dependent decrease in invasion at these 
doses, but they were non-cytotoxic. Therefore, it cannot be determined if the decrease of 
invasion occurred because IB inhibits the invasion signaling pathway, or because IB 
killed more cells before they had time to invade. The cytotoxicity was caused by using a 
10 μM stock solution of IB in ethanol. It was determined that the ethanol may have 
degraded the IB from its original structure. Thus, for all future experiments, IB in ethanol 
solutions must be made fresh before treating cells. This should result in all IB treatments 
below 10 μM to be non-cytotoxic, as seen previously. 
The inconclusive results of the preliminary invasion assays were likely caused by 



























error. First, wiping the top of the inserts with a cotton swab does not ensure that all of the 
cells counted are actually on the bottom of the inserts. The DAPI stain used is also able to 
go through the basement membranes of the inserts and stain the cells on the top. 
Additionally, the manual cell counting method is subject to human error if there were 
overlapping cells, or if there were cells out of focus. Finally, the results of cytotoxicity 
assay could be caused over-seeding the cells. If the cell density is too high, cell death that 
is not caused by IB will occur due to cell crowding. To improve the accuracy of future 
experiments, these possible sources for error should be eliminated. 
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CHAPTER 3 
IN VITRO STUDIES OF IMIPRAMINE BLUE  
1.1 Introduction 
 In order to eliminate the human error of the in vitro experiments, some changes 
were made to the invasion assay and cytotoxicity protocols. First, fluoroblocking well 
inserts were used in all subsequent invasion assays. These inserts eliminate the need to 
wipe the top of the wells with a cotton swab because they do not let the fluorescent light 
through to the top of the insert. Additionally, GFP fluorescing cells were used, and 
invading cells were counted with a fluorescent plate reader. Using a fluorescent plate 
reader eliminates the human error of manual cell counting, and also eliminates the need 
for fixing with paraformaldehyde and DAPI staining. Eliminating the DAPI staining 
procedure provides the possibility to read the invasion assay at multiple time points. 
Finally, the cell seeding density for the cytotoxicity study was decreased to ensure that 
cell death due to over-confluence did not occur.  
3.2 Methods  
3.2.1 Invasion Assays 
Invasion assays were performed on MatLyLu cells in conjunction with RT2 cells to 
determine the optimal dose of IB for future in vivo testing. Cells were treated with varied 
doses of IB, 0µM, 0.2µM 1µM, 2µM, and with a sample size of n=3. Assays are 
performed in fluroblocking cell culture transwells with 0.8 μm pores that are set in 24 
well plates. The tops of the transwells were coated with 80μL of 0.1X basement 
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membrane extract in 1X coating buffer (Cultrex). The BME was changed from 1X to 
0.1X in order to allow more cells to invade through the transwells. Inserts were incubated 
for 24 hours, and then excess liquid is removed by aspiration. Cells were suspended in 
serum-free media and seeded at a density of 1.5e6 cells per well. Cell seeding density 
was reduced to 1e5 cells/well in later experiments. Serum-containing media is loaded on 
the outside of the inserts to promote cell migration. Transwells were then incubated for 
30 minutes to allow cell adhesion before IB was added. IB was prepared by dissolving in 
ethanol (10 mM), then further diluted with serum free media before adding to each well 
for a final concentration ranging from 0-10 μM IB. Final ethanol content in each well was 
0.5%. After treating with IB, inserts were incubated overnight to allow invading cells to 
migrate through the BME gel. Fluorescence was read with 485/520 excitation/emission 
from the bottom of each well to identify GFP expressing cells that invaded through the 
gel. Invasion was evaluated at 24, 48 and 72 hours. 
3.2.2 Cytotoxicity Assays 
 Cytotoxicity assays were performed on MatLyLu cells in conjunction with RT2 
cells to determine if the tested doses of IB were below cytotoxic levels. Cells were treated 
with varied doses of IB (0 µM, 0.2 µM 1µM, 2 µM) and with a sample size of 3. A single 
well in a 24 well plate had 1e4 cells/well. After 2.5 hours, the drug is added to the wells, 
and the plate was incubated at 37°C overnight. After 24 hours, the drug is removed and a 
10% cell-counting kit 8 (CCK-8) solution in serum containing media is added to each 
well. The CCK-8 indicates NADH production from the dehydrogenase enzyme by 
changing the fluorescence of the cell solution. Viable cells will turn the CCK-8 solution 
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yellow. As the cells die, less NADH will be produced, due to less enzyme activity, and 
the solution will remain red. Cell viability is measured by fluorescence at 24, 48, and 72 
hours with an absorbance of 450 ηm. 
3.3 Results 
Invasion assays were performed on MatLyLu and RT2 cells. The doses of IB tested 
on MatLyLu were 0 µM, 0.2 µM 1 µM, and 2 µM. The doses tested on RT2 were 0 µM, 
and 2 µM. At a seeding density of 1.5e6 cells/well, neither cell line showed a dose-
dependent decrease in invasion (Fig. 3.1). However, cytotoxicity was tested on both cell 
lines at the same doses of IB, and none of the tested doses showed cytotoxicity (Fig. 3.2 
and 3.3). Thus, the invasion assays of Fig. 3.1 have yielded no conclusive results. 
However, another invasion assay study was performed on both cell lines after reducing 
cell seeding density to 1e5 cells/well. Doses tested on the MatLyLu line were 0 µM, 0.2 
µM 1µM, 2 µM, and 10 µM. Doses tested on the RT2 cell line were 0 µM, 2 µM, and 10 
µM. Results from this experiment show a dose-dependent decrease in invasion in the RT2 
cell line, but not in the MatLyLu cell line, seen in Fig. 3.4. This assay was read again at 









Figure 3.1: Effects of IB below 2 μM on MatLyLu (A) and RT2 (B) on invasion. In 
vitro invasion assays were performed on MatLyLu (A) and RT2 (B) cell lines. Doses 
tested on MatLyLu were 0.2 µM, 1 µM, and 2 µM. The dose tested on RT2, the positive 
control, was 2 µM. The negative control for both cell lines was 0 µM IB. A dose 
dependent decrease of invasion was not seen in either cell line at seeding density, 1.5e6 
cells/well. 
 
Figure 3.2: Cytotoxicity of IB on MatLyLu at doses below 2µM. An in vitro 
cytotoxicity assay was performed on the MatLyLu cell line. Doses tested were 0 µM, 0.2 

















































Figure 3.3: Cytotoxicity of IB on RT2 at doses below 2 µM. An in vitro cytotoxicity 
assay was performed on the MatLyLu cell line. Concentration of IB tested were 0 µM, 






















Figure 3.4: Invasion assay of MatLyLu and RT2 with IB doses below 10 μM. In vitro 
invasion assays were performed on MatLyLu  and RT2 cell lines. Doses tested on 
MatLyLu were 0 µM, 0.2 µM, 1µM, 2 µM, and 10 µM. Doses tested on RT2 were 0 µM, 
2 µM, and 10 µM. A dose dependent decrease of invasion was seen in RT2, but not in 
MatLyLu after 24 hour exposure. An unpaired, two-tailed t-test was performed to test for 
significance of RT2 invasion between 0 µM and 2 µM IB. A statistically significant 























Figure 3.5: 48 hour reading of MatLyLu (A) and RT2 (B) invasion assay. In vitro 
invasion assays were incubated for an additional 48 hours, and fluorescence was 
measured. A dose dependent decrease of invasion was still seen in RT2, but not in 
MatLyLu. An unpaired, two-tailed t-test was performed to test for significance of RT2 
invasion between 0uM and 2uM IB. Results were found to be statistically significant and 

























Figure 3.6.  Day 7 reading of MatLyLu (A) and RT2 (B) invasion assay. In vitro 
invasion assays were monitored for a week, and on day 7, fluorescence was measured. A 
dose dependent decrease of invasion was still seen in RT2, but no significant change was 




















significance of RT2 invasion between 0uM and 2uM IB. No statistical significance was 
determined (p-value >0.05*). 
3.4 Discussion 
 Results from Figs. 3.1-3.3 indicate that although IB is no longer cytotoxic and that 
there is no dose dependent decrease in invasion. However, this result is likely caused by 
the high cell seeding density of the invasion assay. For this assay, the cell seeding density 
was increased significantly, from 5e5 cells/well to 1.5e6 cells/well. An extremely high 
cell seeding density was chosen to ensure the plate reader would be able to read the 
fluorescence of the cells. However, once it was determined that using the plate reader was 
a viable method for evaluating the number of invaded cells, the seeding density was 
decreased for the final experiment.   
 Therefore, a final invasion assay with a cell seeding density of 1e5 cells/well was 
performed. The results showed that the RT2 cells experienced a dose dependent decrease 
in invasion, as expected, and at least the 2 µM dose was known to be non-cytotoxic. This 
result indicates that the new method for testing invasion is a viable one. However, a dose 
dependent decrease in invasion was not observed for the MatLyLu cells, even after 7 
days. On day 7 the invasion assay was observed under a fluorescent microscope and 
images revealed that none of the MatLyLu cells, IB treated or not, experienced 
significant invasion. Thus, it was determined that the reason a dose dependent decrease of 
invasion was not seen was because the cells did not invade under any condition. 
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CHAPTER 4 
MOVING FORWARD IN VIVO 
4.1 Overall Discussion of In Vitro Testing 
The future direction of cancer treatment includes the addition of anti-invasive agents 
to supplement current cancer treatment. Recently there have been significant advances in 
the development and evaluation of anti-invasive compounds. Specifically, Munson et al. 
tested IB on a highly invasive glioblastoma model. Their research showed that IB 
significantly decreased invasion in vitro at non-cytotoxic levels. Because IB is thought to 
act by disrupting a signaling pathway cells use for invasion, it is believed to be a 
universally good anti-invasive therapeutic.  
However, results thus far have not provided enough evidence to determine whether or 
not IB halts the invasion of the MatLyLu cell line. In the most recent invasion assay 
experiment, none of the MatLyLu cells invaded, including the cells not treated with IB. 
Conversely, the glioblastoma cell line did experience a dose dependent decrease in 
invasion. This supports the results of Munson et al. and indicates that the method for 
performing the invasion assay is adequate.  
A final invasion assay experiment should be optimized to promote MatLyLu 
invasion. At a density of 1.5e6 cells/well, invasion was observed, but no reduction was 
observed. At 1e5 cells/well, invasion was not observed. Thus, the most likely cause of the 
MatLyLu’s lack of invasion is the cell seeding density. Although this is the optimal cell 
seeding density for the RT2 cells, RT2 cells are known to be more invasive than 
MatLyLu cells. A higher cell seeding density may be needed to further promote the 
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MatLyLu cells to invade. To complete this section of the project, a seeding density 
optimization experiment should be performed on the MatLyLu cell line. Once 
determined, a final invasion assay experiment should be performed to evaluate IB’s 
ability to halt the invasion of MatLyLu.  
4.2 In Vivo Model  
 To complete the secondary aim of this project, an in vivo tumor model for 
MatLyLu was developed. Since MatLyLu is known to invade in the lymph nodes and the 
lungs, the lungs of tumor bearing animals were explanted and examined for metastases. 
Primary tumors are surgically resected 10 days after implantation to promote MatLyLu 
metastasis. Matlylu cells were passaged in vivo by inoculating cells into the left flank of 
Copenhagen rats. Once the tumors reached 3 cm in diameter, they were explanted. The 
tumor tissue was subjected to mechanical dissociation in serum free media to obtain a 
suspension of tumor cells. These cells were then inoculated subcutaneously into the left 
flank of a new rat. Cells were passaged in this manner until they were ready to be utilized 
for in vivo testing. For the metastatic model, approximately 2.5e6 in vivo passaged 
MatLyLu cells were inoculated into the left flank of rats. Tumors were surgically resected 
once they reached 3 cm in diameter. The animals were then allowed to recover, and were 
euthanized 8 days later.  
 Lungs from healthy animals did now show signs of metastasis, and lungs from 
cancerous animals were covered with metastases, as seen in Figure 4.1. This model was 
developed using genetically unaltered MatLyLu cells. However, in future experiments 
this model should be tested with luciferase expressing cells. Luciferase expressing cells 
allows the opportunity to examine metastasis non-invasively, which could allow animal 
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survival studies to be performed in the future. Animals with luciferase expressing tumors 
can be treated with luciferin, and the cells can be tracked through bioluminescent imaging 




Figure 4.1: In vivo tumor model for non-fluorescent MatLyLu cells. Dorsal (A,B) and 
ventral (C,D) views of lungs explanted from rats are present in the lung from the cancer-
bearing animal (A,C) but not in the lung from the healthy animal (B,D). Scale bar is 1cm.  
4.3 Conclusion 
 In conclusion, more experiments need to be done for both the in vitro and in vivo 
models before the effects of IB can be tested in vivo on MatLyLu. The lowest effective 
dose of IB on MatLyLu is yet to be determined, although the experimental method for 
testing this has been finalized. Additionally, the in vivo tumor model should be tested 
with luciferase expressing cells so metastasis can be tracked non-invasively. Once both of 
these tests are finalized, this project will be ready to move forward to test IB in vivo.  
1cm 1cm 
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